Physician profile
David E Meyer
NPI 1861704850
$1,554.45
in general payments reported to CMS, 2019-2025
19 companies · $411 in 2025
The $411 reported for 2025 was more than what a typical Critical Care Medicine (Internal Medicine) provider received nationally (typical 2025 total: $189).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $597 · 2020: $149 · 2021: $39.13 · 2022: $140 · 2023: $32.99 · 2024: $185 · 2025: $411.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $629.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $629.09 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Leo Pharma INC. | $269.39 | 2020-2025 | Adbry, Anzupgo |
| Zimmer Biomet Holdings, INC. | $158.32 | 2019-2021 | |
| Smith+Nephew, INC. | $140.01 | 2025 | Real Intelligence |
| Galderma Laboratories, L.P. | $123.04 | 2023-2025 | Dysport |
| Baxter Healthcare | $111.15 | 2019 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $110.59 | 2019-2024 | Jublia, Arazlo, Cabtreo |
| Kci USA, INC. | $104.23 | 2020 | |
| Acell, INC. | $87.83 | 2019 | |
| Dusa Pharmaceuticals, INC. | $81.74 | 2019 | |
| Tela Bio, INC. | $71.05 | 2019 | |
| Incyte Corporation | $52.38 | 2025 | Opzelura |
| Almirall LLC | $48.09 | 2019-2022 | |
| Wound Management Technologies, INC | $44.80 | 2019 | |
| Aroa Biosurgery Incorporated | $42.41 | 2022 | |
| Biofrontera INC. | $41.70 | 2024 | Ameluz, Xepi, Bf-Rhodoled |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Depuy Synthes Sales INC. | $28.34 | 2019-2020 | |
| Novo Nordisk INC | $20.48 | 2025 | Wegovy |
| Sun Pharmaceutical Industries INC. | $18.90 | 2021 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Meyer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.